BS
Therapeutic Areas
Praxis Precision Medicines Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Ulixacaltamide (PRAX-944) | Essential Tremor | Phase 3 |
| PRAX-628 | Focal Onset Seizures | Phase 3 |
| Elsunacaltamide (PRAX-222) | SCN2A or SCN8A Developmental and Epileptic Encephalopathy (DEE) | Phase 2/3 |
| PRAX-562 | Developmental and Epileptic Encephalopathies (DEEs) | Phase 2 |
Leadership Team at Praxis Precision Medicines
MS
Marcio Souza
President & Chief Executive Officer
SP
Steve Petrou
Co-Founder, President of Research & Development
AW
Alyssa Wyant
Chief Regulatory & Quality Officer
TK
Tim Kelly
Chief Financial Officer
KM
Kelly McCue
Chief People Officer
KH
Karl Hansen
Chief Technical Operations Officer
MS
Megan Sniecinski
Chief Operating Officer
AN
Alex Nemiroff
General Counsel
DM
Dean Mitchell
Chairman of the Board
DM
Dr. Merit Cudkowicz
Director